share_log

Phreesia, Inc. (NYSE:PHR) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates

Phreesia, Inc. (NYSE:PHR) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates

Phreesia, Inc. (紐交所:PHR) 剛發布了第一季度業績,分析師正在更新其估計。
Simply Wall St ·  06/05 09:14

There's been a notable change in appetite for Phreesia, Inc. (NYSE:PHR) shares in the week since its first-quarter report, with the stock down 18% to US$18.62. Revenues of US$101m arrived in line with expectations, although statutory losses per share were US$0.35, an impressive 30% smaller than what broker models predicted. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year.

自第一季度報告以來,Phreesia公司(紐交所:PHR)股票在過去一週中受到了明顯的拋售,股價下跌18%至18.62美元。營業收入達到1.01億美元,符合預期,儘管每股虧損爲0.35美元,但比經紀公司模型預測的虧損小30%,給投資者提供了一個重要的參考,通過公司報告可以跟蹤公司業績,查看專家對明年業績的預測,了解業務預期是否有改變。所以我們收集了最新的盈利法規共識估計,以查看明年可能的情況。

earnings-and-revenue-growth
NYSE:PHR Earnings and Revenue Growth June 5th 2024
紐交所:PHR收益和營業收入增長2024年6月5日

Following the latest results, Phreesia's 16 analysts are now forecasting revenues of US$420.9m in 2025. This would be a solid 13% improvement in revenue compared to the last 12 months. Losses are predicted to fall substantially, shrinking 39% to US$1.27. Before this latest report, the consensus had been expecting revenues of US$427.7m and US$1.66 per share in losses. While the revenue estimates were largely unchanged, sentiment seems to have improved, with the analysts upgrading their numbers and making a very promising decrease in losses per share in particular.

根據最新的結果,Phreesia的16名分析師預測2025年營業額將達到4.209億美元,相比過去12個月增加了13%,同時預計虧損將大幅減少,縮小39%至1.27美金。在這一最新報告發布之前,共識曾預計營業額爲4.277億美金,每股虧損爲1.66美金。儘管營收預測基本未變,但微弱的情緒改善似乎提高了分析師們的預期,尤其是減少每股虧損的前景看起來非常有前途。

There's been no major changes to the consensus price target of US$29.13, suggesting that reduced loss estimates are not enough to have a long-term positive impact on the stock's valuation. There's another way to think about price targets though, and that's to look at the range of price targets put forward by analysts, because a wide range of estimates could suggest a diverse view on possible outcomes for the business. Currently, the most bullish analyst values Phreesia at US$34.00 per share, while the most bearish prices it at US$23.00. Analysts definitely have varying views on the business, but the spread of estimates is not wide enough in our view to suggest that extreme outcomes could await Phreesia shareholders.

美元29.13的共識目標價沒有發生重大變化,這意味着減少虧損估計並不足以對股票的估值產生長期積極的影響。然而,有另一種思考價格目標的方式,就是看看分析師提出的價格目標區間,因爲廣泛的估計範圍可能意味着業務可能有多種可能的結果。目前,最看好的分析師將Phreesia的估值定爲每股34.00美元,而最看淡的估值將其定爲23.00美元。分析師確實對業務持有不同的觀點,但我們認爲估計的差距不足以暗示Phreesia股東將會面臨極端結果。

Of course, another way to look at these forecasts is to place them into context against the industry itself. It's pretty clear that there is an expectation that Phreesia's revenue growth will slow down substantially, with revenues to the end of 2025 expected to display 17% growth on an annualised basis. This is compared to a historical growth rate of 26% over the past five years. By way of comparison, the other companies in this industry with analyst coverage are forecast to grow their revenue at 10% annually. So it's pretty clear that, while Phreesia's revenue growth is expected to slow, it's still expected to grow faster than the industry itself.

當然,看待這些預測的另一種方式是將它們放在行業本身的背景下。很明顯,人們預計Phreesia的營業收入增長將大幅放緩,到2025年末預計年化增長率將爲17%。相比之下,這個行業中其他受到分析師關注的公司預計其營業收入年均增長10%。所以可以很清楚地看出,儘管Phreesia的營收增長預計將放緩,但相比於整個行業,它仍有望增長得更快。

The Bottom Line

最重要的事情是分析師增加了它對下一年每股虧損的估計。令人欣慰的是,營收預測未發生重大變化,業務仍有望比整個行業增長更快。共識價格目標穩定在28.50美元,最新估計不足以對價格目標產生影響。

The most important thing to take away is that the analysts reconfirmed their loss per share estimates for next year. Fortunately, they also reconfirmed their revenue numbers, suggesting that it's tracking in line with expectations. Additionally, our data suggests that revenue is expected to grow faster than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.

最重要的是,分析師們確認了下一年每股虧損的預測數。幸運的是,他們還確認了收入數字,表明它正在符合預期。此外,我們的數據表明,收入預計將比整個行業增長更快。共識目標價沒有發生實質性變化,說明最新的估計並沒有使該業務的內在價值發生重大變化。

Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. At Simply Wall St, we have a full range of analyst estimates for Phreesia going out to 2027, and you can see them free on our platform here..

由此可以推斷出,我們認爲業務的長期前景比明年的收益更爲相關。在Simply Wall St上,我們爲Phreesia公司展示從現在到2027年的分析師預測範圍,您可以在我們的平台上免費查看。

However, before you get too enthused, we've discovered 4 warning signs for Phreesia (1 is a bit unpleasant!) that you should be aware of.

但在您過度熱衷之前,我們已發現Phreesia有4個警告信號(其中1個有點不愉快!),您應該注意。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有反饋?關於內容有所顧慮?直接和我們聯繫。或電郵 editorial-team (at) simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論